# Vitamin D3 (5,000 IU) + K2-MK7 Protocol - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Vitamin D3 supplementation reduces cancer mortality by 13% in meta-analyses (Keum N, et al., Ann Oncol 2019). K2-MK7 prevents arterial stiffness (Knapen MH, et al., Thromb Haemost 2015).

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **85/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 73/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
1,25-dihydroxyvitamin D binds to VDR nuclear receptors, promoting transcription of antimicrobial peptides (cathelicidin) and suppressing inflammatory IL-6/TNF-alpha cytokines. K2 carboxylation directs calcium into bone matrix.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **82/100** [Rank #33 of 133 in Heart] - Effect: Prevents arterial calcification by carboxylating Matrix Gla Protein (MGP)
    - Mechanism: Carboxylates Matrix Gla Protein (MGP), the strongest endogenous inhibitor of vascular soft-tissue and coronary arterial calcification.
- **Bone Density & Connective Matrix**: **93/100** [Rank #6 of 142 in Bone Matrix] - Effect: Significantly increases bone mineral density and decreases age-related bone mineral loss
    - Mechanism: Vitamin D3 upregulates intestinal calcium absorption proteins while Vitamin K2 (Menaquinone-7) serves as the obligate co-factor for gamma-glutamyl carboxylase, activating osteocalcin to bind calcium into hydroxyapatite.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 5,000 IU D3 + 100mcg K2-MK7
- **Recommended Timing**: Early Morning (06:30 AM)
- **Administration Type**: supplement
- **Recommended Biomarkers to Monitor**: energy, calmness, bone_density, heart_health

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: None reported in standard human trials with recommended doses.
- **Safety Profile**: safe - Test serum 25(OH)D levels twice annually to maintain optimal 40–60 ng/mL window.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women** [PMID: 23525894]
   - Link: https://pubmed.ncbi.nlm.nih.gov/23525894/
2. **The synergistic interrelationship between Vitamin D and Vitamin K for bone and cardiovascular health** [PMID: 31530136]
   - Link: https://pubmed.ncbi.nlm.nih.gov/31530136/
3. **Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women** [PMID: 25694037]
   - Link: https://pubmed.ncbi.nlm.nih.gov/25694037/
4. **Vitamin D Supplementation to Prevent Acute Respiratory Tract Infections: Systematic Review and Meta-Analysis of Individual Participant Data** [PMID: 28202713]
   - Link: https://pubmed.ncbi.nlm.nih.gov/28202713/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Vitamin D3 (5,000 IU) + K2-MK7 Protocol on LongevityReviews](https://longevityreviews.org/modalities/rhonda_vitamin_d3_k2)
- **Last Evidence Calibration**: 2026-08-08
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.